Jiangsu poised to fuel development of biopharmaceutical industry cluster

Jiangsu province will strengthen the source of technological innovation, build a good industrial ecology, promote the development of integrated clusters, create a more competitive highland for the innovation and development of biomedicine, and accelerate the construction of strategic emerging industry clusters with international competitiveness. The remark was made by Xin Changxing, Secretary of the Provincial Party Committee, on February 12th and 13th when he made an inspection tour to industrial parks, enterprises and universities in Nanjing and Suzhou on the development of the biopharmaceutical industry cluster.

Kingsray Biotechnology Co., Ltd. is a well-known provider of life science products and services, incubating multiple unicorn and small giant enterprises.

When visiting the exhibition hall and production line of Kingsray Biotechnology Co. Ltd. Xin Changxing made detailed inquiry into the company's development history, main business segments, research and development of cell and gene therapy products and AI technology applications. He encouraged the company to gather a first-class innovation team, develop "AI+biopharmaceutical" technology, improve research and development efficiency, and develop innovative drugs based on new structures, new targets, and new mechanisms.

During a visit to Jiangyuan Andike Positron Research and Development Co., Ltd., Xin Changxing pointed out that nuclear medicine has shown good application prospects in early diagnosis and precision treatment. Enterprises should develop more new drugs and high-end diagnostic and treatment equipment while ensuring safety in order to better benefit the general public.

Suzhou Biomedical Industry Park has gathered more than 620 innovative pharmaceutical enterprises, especially a group of multinational pharmaceutical companies, making the park's comprehensive competitiveness among the top in the country.

When inspecting the innovative achievements of drugs and medical devices, Xin Changxing made a detailed understanding of the company's technology research and development, achievement transformation, public listing and financing, and overseas market expansion. He spoke highly of the achievements the park has made in promoting the development of the biopharmaceutical industry over the years.

Noting that biopharmaceuticals are a sunrise industry with high investment, high risk, and long cycle, he requested that the company support the innovation and development of enterprises throughout the entire chain, including research and development, clinical practice, manufacturing, and application.

Yasheng Pharmaceutical Co., Ltd. is committed to addressing the unmet clinical needs of patients in fields such as hematological oncology. Xin Changxing visited its laboratory and production workshop to learn about the sales of innovative drugs and the progress of products under research. He encouraged the company to focus on cutting-edge fields, grasp the global market, and lead the industry development with more original achievements to enhance competitive advantages.

When presiding over a symposium during the inspection tour, Xin Changxing emphasized that the biopharmaceutical industry is a strategic emerging industry that is related to national economy, people's livelihood, and national security that is undergoing disruptive changes. As a result, Jiangsu will focus on technological innovation as the source, enhance the level of innovation platforms, promote the timely transformation of technological achievements into new products and industries, and enhance the health and well-being of the people.